The recommendations for the use of the first licensed HPV vaccine (Gardasil[R], Merck) were published by NACI in February 2007.
Since 2001, NACI has recommended meningococcal C conjugate vaccine for children <1 year of age, children from 1-4 years of age, adolescents, and young adults.
In 2002, NACI recommended that all adolescents should receive a single booster dose of the adolescent/adult formulation of the Tdap vaccine, as well as adults who have not previously received a dose.
Although NACI produces statements on its recommendations for immunizations, it is up to the individual provinces and territories as to what vaccine programs they choose to implement and fund.
21) After the vaccine is approved for use, NACI reviews and summarizes the studies, evaluating the level and quality of the evidence, and makes a recommendation regarding the use of the vaccine.